Byrd JC - Search Results

1

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.

Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC. Mone AP, et al. Among authors: byrd jc. Leukemia. 2006 Feb;20(2):272-9. doi: 10.1038/sj.leu.2404014. Leukemia. 2006. PMID: 16341049

2

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR. Byrd JC, et al. Blood. 1998 Nov 15;92(10):3804-16. Blood. 1998. PMID: 9808574 Free article.

3

Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.

Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. Byrd JC, et al. Blood. 1999 Aug 15;94(4):1401-8. Blood. 1999. PMID: 10438728 Free article.

4

Update on the biology of chronic lymphocytic leukemia.

Bannerji R, Byrd JC. Bannerji R, et al. Among authors: byrd jc. Curr Opin Oncol. 2000 Jan;12(1):22-9. doi: 10.1097/00001622-200001000-00004. Curr Opin Oncol. 2000. PMID: 10687725 Review.

5

Novel therapies for chronic lymphocytic leukemia in the 21st century.

Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Byrd JC, et al. Semin Oncol. 2000 Oct;27(5):587-97. Semin Oncol. 2000. PMID: 11049025 Review.

6

Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia.

Waselenko JK, Grever MR, Shinn CA, Flinn IW, Byrd JC. Waselenko JK, et al. Among authors: byrd jc. Leuk Res. 2001 Jun;25(6):435-40. doi: 10.1016/s0145-2126(00)00106-5. Leuk Res. 2001. PMID: 11337014

7

Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells.

Waselenko JK, Shinn CA, Willis CR, Flinn IW, Grever MR, Byrd JC. Waselenko JK, et al. Among authors: byrd jc. Leuk Lymphoma. 2001 Sep-Oct;42(5):1049-53. doi: 10.3109/10428190109097725. Leuk Lymphoma. 2001. PMID: 11697622

8

Antibody therapy of acute and chronic leukemias.

Cataland SR, Lucas M, Byrd JC. Cataland SR, et al. Among authors: byrd jc. Curr Pharm Biotechnol. 2001 Dec;2(4):357-67. doi: 10.2174/1389201013378608. Curr Pharm Biotechnol. 2001. PMID: 11762417 Review.

9

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C. Byrd JC, et al. Leukemia. 2003 Feb;17(2):323-7. doi: 10.1038/sj.leu.2402752. Leukemia. 2003. PMID: 12592330 Clinical Trial.

10

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G. Klisovic MI, et al. Among authors: byrd jc. Leukemia. 2003 Feb;17(2):350-8. doi: 10.1038/sj.leu.2402776. Leukemia. 2003. PMID: 12592335

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

861 results

Search Page

Filters